Erratum: The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation (Science Signaling (2017) 10 (eaal2021) DOI: 10.1126/scisignal.aal2021);The amyloid-β oligomer Aβ∗56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation

Science Signaling

Volumn 10, Issue 478, 2017, Pages

  Amar, Fatou ^a,b,f   Sherman, Mathew A ^a,b   Rush, Travis ^c,g   Larson, Megan ^a,b,h   Boyle, Gabriel ^a,b   Chang, Liu ^d   Götz, Jürgen ^e   Buisson, Alain ^c   Lesné, Sylvain E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f University of Alabama at Birmingham ^*  (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Bio Techne Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA OLIGOMER PROTEIN 56; AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IIALPHA; CALCIUM ION; CYCLIN DEPENDENT KINASE 5; EPHRIN B2; GLUTAMATE RECEPTOR 5; GLYCOGEN SYNTHASE KINASE 3BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; PRION PROTEIN; TAU PROTEIN; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; CALCIUM;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; FEMALE; INTRACELLULAR SIGNALING; MOUSE; NERVE CELL CULTURE; NONHUMAN; POSTSYNAPTIC DENSITY; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; BRAIN; CELL CULTURE; CHEMISTRY; CYTOLOGY; GENETICS; HUMAN; MALE; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELLS, CULTURED; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 85019231994     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.add4322     Document Type: Erratum

References (73)

1. M. Jin, N. Shepardson, T. Yang, G. Chen, D. Walsh, D. J. Selkoe, Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U. S. A. 108, 5819-5824 (2011).
2. c-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J. Neurosci. 32, 16857-16871 (2012).
3. G. Mairet-Coello, J. Courchet, S. Pieraut, V. Courchet, A. Maximov, F. Polleux, The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through tau phosphorylation. Neuron 78, 94-108 (2013).
4. E. D. Roberson, K. Scearce-Levie, J. J. Palop, F. Yan, I. H. Cheng, T. Wu, H. Gerstein, G.-Q. Yu, L. Mucke, Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007).
5. L. M. Ittner, J. Götz, Amyloid-β and tau-A toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65-72 (2011).
6. J. P. Cleary, D. M. Walsh, J. J. Hofmeister, G. M. Shankar, M. A. Kuskowski, D. J. Selkoe, K. H. Ashe, Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84 (2005).
7. M. N. Reed, J. J. Hofmeister, L. Jungbauer, A. T. Welzel, C. Yu, M. A. Sherman, S. Lesné, M. J. LaDu, D. M. Walsh, K. H. Ashe, J. P. Cleary, Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging 32, 1784-1794 (2011).
8. S. Lesné, M. T. Koh, L. Kotilinek, R. Kayed, C. G. Glabe, A. Yang, M. Gallagher, K. H. Ashe, A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
9. G. M. Shankar, S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I. Smith, F. M. Brett, M. A. Farrell, M. J. Rowan, C. A. Lemere, C. M. Regan, D. M. Walsh, B. L. Sabatini, D. J. Selkoe, Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
10. D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan, D. J. Selkoe, Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
11. M. Townsend, J. P. Cleary, T. Mehta, J. Hofmeister, S. Lesne, E. O'Hare, D. M. Walsh, D. J. Selkoe, Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers. Ann. Neurol. 60, 668-676 (2006).
12. S. Oddo, V. Vasilevko, A. Caccamo, M. Kitazawa, D. H. Cribbs, F. M. LaFerla, Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 39413-39423 (2006).
13. I. H. Cheng, K. Scearce-Levie, J. Legleiter, J. J. Palop, H. Gerstein, N. Bien-Ly, J. Puoliväli, S. Lesné, K. H. Ashe, P. J. Muchowski, L. Mucke, Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828 (2007).
14. W. J. Meilandt, M. Cisse, K. Ho, T. Wu, L. A. Esposito, K. Scearce-Levie, I. H. Cheng, G.-Q. Yu, L. Mucke, Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci. 29, 1977-1986 (2009).
15. G. Leinenga, J. Götz, Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci. Transl. Med. 7, 278ra233 (2015).
16. S. E. Lesné, M. A. Sherman, M. Grant, M. Kuskowski, J. A. Schneider, D. A. Bennett, K. H. Ashe, Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398 (2013).
17. T. A. Salthouse, When does age-related cognitive decline begin? Neurobiol. Aging 30, 507-514 (2009).
18. A. Savioz, P. Giannakopoulos, F. R. Herrmann, W. L. Klein, E. Kövari, C. Bouras, E. Giacobini, A study of Aβ oligomers in the temporal cortex and cerebellum of patients with neuropathologically confirmed Alzheimer's disease compared to aged controls. Neurodegener. Dis. 16, 398-406 (2016).
19. M. E. Larson, M. A. Sherman, S. Greimel, M. Kuskowski, J. A. Schneider, D. A. Bennett, S. E. Lesné, Soluble a-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J. Neurosci. 32, 10253-10266 (2012).
20. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
21. M. A. Sherman, S. E. Lesné, Detecting aβ∗56 oligomers in brain tissues. Methods Mol. Biol. 670, 45-56 (2011).
22. P. Liu, M. N. Reed, L. A. Kotilinek, M. K. O. Grant, C. L. Forster, W. Qiang, S. L. Shapiro, J. H. Reichl, A. C. A. Chiang, J. L. Jankowsky, C. M. Wilmot, J. P. Cleary, K. R. Zahs, K. H. Ashe, Quaternary structure defines a large class of amyloid-β oligomers neutralized by sequestration. Cell Rep. 11, 1760-1771 (2015).
23. M. L. Frandemiche, S. De Seranno, T. Rush, E. Borel, A. Elie, I. Arnal, F. Lanté, A. Buisson, Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-β oligomers. J. Neurosci. 34, 6084-6097 (2014).
24. F. El Gaamouch, A. Buisson, O. Moustié, M. Lemieux, S. Labrecque, B. Bontempi, P. De Koninck, O. Nicole, Interaction between aCaMKII and GluN2B controls ERK-dependent plasticity. J. Neurosci. 32, 10767-10779 (2012).
25. K. Bordji, J. Becerril-Ortega, O. Nicole, A. Buisson, Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J. Neurosci. 30, 15927-15942 (2010).
26. F. Léveillé, F. El Gaamouch, E. Gouix, M. Lecocq, D. Lobner, O. Nicole, A. Buisson, Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 22, 4258-4271 (2008).
27. J. W. Um, A. C. Kaufman, M. Kostylev, J. K. Heiss, M. Stagi, H. Takahashi, M. E. Kerrisk, A. Vortmeyer, T. Wisniewski, A. J. Koleske, E. C. Gunther, H. B. Nygaard, S. M. Strittmatter, Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer ab oligomer bound to cellular prion protein. Neuron 79, 887-902 (2013).
28. J. W. Um, H. B. Nygaard, J. K. Heiss, M. A. Kostylev, M. Stagi, A. Vortmeyer, T. Wisniewski, E. C. Gunther, S. M. Strittmatter, Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227-1235 (2012).
29. J. Laurén, D. A. Gimbel, H. B. Nygaard, J. W. Gilbert, S. M. Strittmatter, Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457, 1128-1132 (2009).
30. T.-W. Chen, T. J. Wardill, Y. Sun, S. R. Pulver, S. L. Renninger, A. Baohan, E. R. Schreiter, R. A. Kerr, M. B. Orger, V. Jayaraman, L. L. Looger, K. Svoboda, D. S. Kim, Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295-300 (2013).
31. G. E. Hardingham, H. Bading, Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim. Biophys. Acta 1600, 148-153 (2002).
32. G. E. Hardingham, H. Bading, Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696 (2010).
33. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448-6453 (1998).
34. J. Chin, J. J. Palop, G.-Q. Yu, N. Kojima, E. Masliah, L. Mucke, Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24, 4692-4697 (2004).
35. J. Chin, J. J. Palop, J. Puoliväli, C. Massaro, N. Bien-Ly, H. Gerstein, K. Scearce-Levie, E. Masliah, L. Mucke, Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25, 9694-9703 (2005).
36. E. D. Roberson, B. Halabisky, J. W. Yoo, J. Yao, J. Chin, F. Yan, T. Wu, P. Hamto, N. Devidze, G.-Q. Yu, J. J. Palop, J. L. Noebels, L. Mucke, Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711 (2011).
37. S. J. Coultrap, R. S. Vest, N. M. Ashpole, A. Hudmon, K. U. Bayer, CaMKII in cerebral ischemia. Acta Pharmacol. Sin. 32, 861-872 (2011).
38. 2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J. Neurosci. 24, 5283-5291 (2004).
39. H. Ma, S. Lesné, L. Kotilinek, J. V. Steidl-Nichols, M. Sherman, L. Younkin, S. Younkin, C. Forster, N. Sergeant, A. Delacourte, R. Vassar, M. Citron, P. Kofuji, L. M. Boland, K. H. Ashe, Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 104, 8167-8172 (2007).
40. M. A. Merrill, Y. Chen, S. Strack, J. W. Hell, Activity-driven postsynaptic translocation of CaMKII. Trends Pharmacol. Sci. 26, 645-653 (2005).
41. 2+-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. EMBO J. 9, 3539-3544 (1990).
42. L. Martin, X. Latypova, C. M. Wilson, A. Magnaudeix, M.-L. Perrin, C. Yardin, F. Terro, Tau protein kinases: Involvement in Alzheimer's disease. Ageing Res. Rev. 12, 289-309 (2013).
43. C. Liu, J. Götz, Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLOS ONE 8, e84849 (2013).
44. B. R. Hoover, M. N. Reed, J. Su, R. D. Penrod, L. A. Kotilinek, M. K. Grant, R. Pitstick, G. A. Carlson, L. M. Lanier, L.-L. Yuan, K. H. Ashe, D. Liao, Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081 (2010).
45. 2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 11938-11950 (2010).
46. M. A. Sherman, M. LaCroix, F. Amar, M. E. Larson, C. Forster, A. Aguzzi, D. A. Bennett, M. Ramsden, S. E. Lesné, Soluble conformers of Aβ and tau alter selective proteins governing axonal transport. J. Neurosci. 36, 9647-9658 (2016).
47. M. Aarts, Y. Liu, L. Liu, S. Besshoh, M. Arundine, J. W. Gurd, Y.-T. Wang, M. W. Salter, M. Tymianski, Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298, 846-850 (2002).
48. L. M. Ittner, Y. D. Ke, F. Delerue, M. Bi, A. Gladbach, J. van Eersel, H. Wölfing, B. C. Chieng, M. J. Christie, I. A. Napier, A. Eckert, M. Staufenbiel, E. Hardeman, J. Götz, Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142, 387-397 (2010).
49. J. Götz, Y.-A. Lim, Y. D. Ke, A. Eckert, L. M. Ittner, Dissecting toxicity of tau and β-amyloid. Neurodegener. Dis. 7, 10-12 (2010).
50. R. S. Vest, K. D. Davies, H. O'Leary, J. D. Port, K. U. Bayer, Dual mechanism of a natural CaMKII inhibitor. Mol. Biol. Cell 18, 5024-5033 (2007).
51. 2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor. J. Biol. Chem. 285, 20675-20682 (2010).
52. K. Barcomb, J. W. Hell, T. A. Benke, K. U. Bayer, The CaMKII/GluN2B protein interaction maintains synaptic strength. J. Biol. Chem. 291, 16082-16089 (2016).
53. L. T. Haas, S. M. Strittmatter, Oligomers of amyloid β prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease. J. Biol. Chem. 291, 17112-17121 (2016).
54. M. E. Seward, E. Swanson, A. Norambuena, A. Reimann, J. N. Cochran, R. Li, E. D. Roberson, G. S. Bloom, Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J. Cell Sci. 126, 1278-1286 (2013).
55. L. Racioppi, A. R. Means, Calcium/calmodulin-dependent protein kinase kinase 2: Roles in signaling and pathophysiology. J. Biol. Chem. 287, 31658-31665 (2012).
56. M. Morris, G. M. Knudsen, S. Maeda, J. C. Trinidad, A. Ioanoviciu, A. L. Burlingame, L. Mucke, Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183-1189 (2015).
57. G. A. Jicha, A. O'Donnell, C. Weaver, R. Angeletti, P. Davies, Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J. Neurochem. 72, 214-224 (1999).
58. B. Trinczek, J. Biernat, K. Baumann, E.-M. Mandelkow, E. Mandelkow, Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell 6, 1887-1902 (1995).
59. N. A. Simonian, T. Elvhage, A. J. Czernik, P. Greengard, B. T. Hyman, Calcium/calmodulindependent protein kinase II immunostaining is preserved in Alzheimer's disease hippocampal neurons. Brain Res. 657, 294-299 (1994).
60. 2+/calmodulin-dependent protein kinase II levels in Alzheimer's disease. Neuroreport 16, 1809-1813 (2005).
61. 2+/calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. J. Neurochem. 119, 791-804 (2011).
62. M. J. Savage, J. Kalinina, A. Wolfe, K. Tugusheva, R. Korn, T. Cash-Mason, J. W. Maxwell, N. G. Hatcher, S. J. Haugabook, G. Wu, B. J. Howell, J. J. Renger, P. J. Shughrue, A. McCampbell, A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J. Neurosci. 34, 2884-2897 (2014).
63. T. Yang, T. T. O'Malley, D. Kanmert, J. Jerecic, L. R. Zieske, H. Zetterberg, B. T. Hyman, D. M. Walsh, D. J. Selkoe, A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res. Ther. 7, 14 (2015).
64. I. Benilova, E. Karran, B. De Strooper, The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
65. E. J. Weeber, Y.-H. Jiang, Y. Elgersma, A. W. Varga, Y. Carrasquillo, S. E. Brown, J. M. Christian, B. Mirnikjoo, A. Silva, A. L. Beaudet, J. D. Sweatt, Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J. Neurosci. 23, 2634-2644 (2003).
66. Y. Yabuki, N. Shioda, T. Maeda, S. Hiraide, H. Togashi, K. Fukunaga, Aberrant CaMKII activity in the medial prefrontal cortex is associated with cognitive dysfunction in ADHD model rats. Brain Res. 1557, 90-100 (2014).
67. S. E. Lesne, Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue. Swiss Med. Wkly. 144, w14021 (2014).
68. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, G. Cole, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-103 (1996).
69. C. Andorfer, Y. Kress, M. Espinoza, R. de Silva, K. L. Tucker, Y.-A. Barde, K. Duff, P. Davies, Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590 (2003).
70. S. Lesné, C. Ali, C. Gabriel, N. Croci, E. T. MacKenzie, C. G. Glabe, M. Plotkine, C. Marchand-Verrecchia, D. Vivien, A. Buisson, NMDA receptor activation inhibits β-secretase and promotes neuronal amyloid-β production. J. Neurosci. 25, 9367-9377 (2005).
71. S. Lesné, C. Gabriel, D. A. Nelson, E. White, E. T. Mackenzie, D. Vivien, A. Buisson, Akt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicity. J. Biol. Chem. 280, 24941-24947 (2005).
72. S. W. Fowler, A. C. A. Chiang, R. R. Savjani, M. E. Larson, M. A. Sherman, D. R. Schuler, J. R. Cirrito, S. E. Lesné, J. L. Jankowsky, Genetic modulation of soluble aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34, 7871-7885 (2014).
73. M. E. Larson, S. E. Lesné, Soluble Aβ oligomer production and toxicity. J. Neurochem. 120(suppl. 1), 125-139 (2012).